Fennec Pharmaceuticals Inc (TSE:FRX) – Research analysts at Wedbush decreased their Q2 2020 earnings per share estimates for Fennec Pharmaceuticals in a research report issued on Tuesday, February 11th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.13) per share for the quarter, down from their prior estimate of ($0.12). Wedbush also issued estimates for Fennec Pharmaceuticals’ Q3 2020 earnings at ($0.13) EPS, Q4 2020 earnings at $6.40 EPS, FY2020 earnings at $6.01 EPS, FY2021 earnings at $0.89 EPS, FY2022 earnings at $1.73 EPS and FY2023 earnings at $2.66 EPS.

Fennec Pharmaceuticals stock opened at C$10.02 on Friday. The stock has a market capitalization of $173.49 million and a price-to-earnings ratio of -16.40. Fennec Pharmaceuticals has a 52-week low of C$4.35 and a 52-week high of C$10.24. The stock’s 50 day moving average price is C$8.44 and its two-hundred day moving average price is C$6.71.

Fennec Pharmaceuticals (TSE:FRX) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported C($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.31) by C$0.19.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Further Reading: How is a buy-side analyst different from a sell-side analyst?

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.